Search the Newsreel

PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD

PolyPid's D-PLEX₁₀₀, a drug candidate for preventing surgical site infections, has received New Drug Application (NDA) acceptance and Priority Review from the FDA, significantly shortening its target review timeline. This positive development comes shortly after PolyPid secured an exclusive commercialization partnership with Azurity Pharmaceuticals, …

Poly Xverse Refreshes Board and Committee Structure Ahead of August 2026

Gulshan Polyols Limited Revenue Breakdown – NSE:GULPOLY

Polycab India shares gain over 2% in today's session

Poly Property Services Co., Ltd. Class H Revenue Breakdown – HKEX:6049

PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026

PolyPid Ltd. announced it will release its second quarter 2026 financial results and operational highlights on August 12, 2026, before U.S. market opening, followed by a conference call and webcast at 8:30 AM ET. The company will discuss the successful Phase 3 SHIELD II …

PolyPid Schedules 8:30 a.m. Webcast for Aug. 12 Results

PolyPid (Nasdaq: PYPD) announced it will report Q2 2026 financial results and operational highlights on August 12, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update. …

Is Polymetals Resources (ASX:POL) Stock Suitable for Your Portfolio as Endeavor Mine Output Grows?

PolyPid rises as lead product granted FDA priority review

PolyPid's stock increased by over 7% after the FDA granted priority review status for D-PLEX100, its lead product candidate. The FDA accepted PolyPid's New Drug Application for the Israeli biopharma company's product. This priority review indicates the potential for a faster approval process for …

PolyPid (PYPD) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article provides a detailed timeline of PolyPid's (PYPD) FDA-related milestones for its drug D-PLEX100, intended to prevent surgical site infections in colorectal surgery. Key events include the FDA's acceptance of the New Drug Application (NDA) with

PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued

This article analyzes the valuation of Polyrizon Ltd (PLRZ.O) using various financial metrics. It states that PLRZ.O is currently in the "Fair zone" based on its forward PS ratio, with a P/B ratio of 1.12 and a Forward FCF yield of -17.34%. The article …

PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review

PolyPid Ltd. (NASDAQ:PYPD) shares jumped over 11% after the FDA accepted its New Drug Application for D-PLEX100, granting it priority review for preventing surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is …

FDA Acceptance Triggers $15M Payment to PolyPid Under Partnership

PolyPid Ltd. announced that the U.S. FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review, setting a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million milestone payment from Azurity Pharmaceuticals, completing $30 million in …

PolyPid (Nasdaq: PYPD) gets FDA Priority Review and $15M milestone

PolyPid Ltd. announced that the FDA has granted Priority Review for its New Drug Application (NDA) for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery, with a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million …

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid Ltd. announced that the FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review for the prevention of surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is sooner …

PolyNovo (ASX:PNV) Posts Record $150m FY26 Revenue

United Polyfab promoters confirm no new share encumbrances in FY26

Jindal Poly Investment and Finance Co. Ltd. Revenue Breakdown – NSE:JPOLYINVST

PolyPid Ltd. Revenue Breakdown – NASDAQ:PYPD

This page from TradingView provides financial information for PolyPid Ltd. (NASDAQ: PYPD), including an overview of its financials, statements, statistics, dividends, earnings, and segment breakdown. It notes that the market is currently closed with no trades.

ONCY|Oncolytics Biotech Inc|Price:0.750|Chg%:-0.042

This article provides a comprehensive stock analysis of Oncolytics Biotech Inc (ONCY), highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from multiple analysts despite a recent weak stock market performance. The company is developing pelareorep, an immunotherapeutic agent for various cancers, and …

PolyPid Ltd (PYPD) Balance Sheet

This article provides a detailed balance sheet for PolyPid Ltd (PYPD), presenting quarterly and annual financial data dating back to 2013. It includes key financial metrics such as assets, liabilities, and shareholders' equity, allowing users to evaluate the company's financial health, liquidity, and leverage. …

Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Polyrizon Ltd (PLRZ), focusing on its P/E and P/B ratios and fair value. It notes that relevant data for P/E has not yet been disclosed by the company. The stock is currently trading at $12.750, down 9.19%.

Polyrizon Ltd (PLRZ) Cash Flow

This article provides an overview of Polyrizon Ltd's (PLRZ) cash flow statements, including operating, investing, and financing cash flows, along with free cash flow data. It highlights key financial figures such as a -4.53M operating cash flow in fiscal 2025 and an increase of …

Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncolytics Biotech Inc (ONCY). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page presents general stock information for ONCY, including its market …

Polyrizon Ltd (PLRZ) Institutional Confidence

The article provides a snapshot of Polyrizon Ltd (PLRZ) stock performance, showing a 5.99% drop with a closing price of $13.800. It highlights "Institutional Confidence" as one of the analysis dimensions on the TradingKey platform, listing Izraeli (Tomer) as a significant shareholder with 8.00 …

PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for PolyPid Ltd (PYPD), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time periods. The data indicates the stock's historical performance …

Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Polyrizon Ltd (PLRZ). It states that no dividends have been distributed over the past five years and notes a merger event scheduled for May 22, 2025, with a 250→1 ratio.

Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice

Oncolytics Biotech Inc. (ONCY) was granted FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor for 2L+ squamous cell anal cancer, based on promising results from the GOBLET study. Despite this positive development, the company received a Nasdaq compliance notice for …

PolyPid Ltd (PYPD) Institutional Confidence

This article provides a brief overview of institutional confidence in PolyPid Ltd (PYPD), highlighting key institutional shareholders and their recent activity. It lists the number of shares held by major investors like Aurum Ventures M.K.I., Hodges (Rodney), Centaurus Investments Limited, and AIGH Capital Management, …

Polyrizon Ltd (PLRZ) Balance Sheet

This article provides the balance sheet for Polyrizon Ltd (PLRZ), offering both annual and quarterly financial data to assess the company's financial health. It details key metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal periods, along with FAQs explaining important …

Olympia Financial Group Inc. Announces Sale of Raisr Division

Polymetals Resources Exchanges AU$28 Million Endeavor Mine Rehabilitation Bond; Shares Down 3%

Polyplex re-appoints Sanjay Gupta & Associates as cost auditor

Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Oncolytics Biotech Inc (ONCY) shareholder structure, detailing major individual and institutional holdings. It includes a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity. Key individual shareholders like Kirk J Look and Thomas …

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

PolyPid Ltd. and Azurity Pharmaceuticals have signed an exclusive deal worth up to US$330 million for the commercialization of D-PLEX100, an infection-prevention drug, in the U.S. and Canada. The agreement includes an upfront payment of US$15 million, potential milestone payments, and Azurity funding further …

TradingKey

This article provides an income statement overview for Polyrizon Ltd (PLRZ) on TradingKey, detailing both quarterly and annual financial performance. It explains how to interpret the income statement, highlights the difference between quarterly and annual data, defines 'YOY,' and lists key metrics for analyzing …